This article covers Zya, a UK-based foodtech startup, which has closed a series A funding round of £11.3m led by Astanor to advance an enzyme ingredient that converts roughly 30% of sucrose in certain foods into prebiotic fibre. The development aims to support food manufacturers and the foodtech ecosystem by funding human studies, regulatory work and commercial partnerships as Zya targets first launches with US manufacturers by the end of 2027.
Zya, a UK-based foodtech startup, has closed a series A funding round of £11.3m led by Astanor to advance an enzyme ingredient that converts roughly 30% of sucrose in certain foods into prebiotic fibre after consumption. The raise — which also attracted Ahren Innovation Capital, Red Bull Ventures, Zubi Capital, Phase Change and Meach Cove Capital — will fund human studies, regulatory work and commercial partnerships as Zya targets first launches with US manufacturers by the end of 2027.
Sugar reduction is a long-standing technical and commercial headache for food manufacturers because sugar performs structural and sensory roles that are hard to replicate. Zya’s approach aims to avoid reformulation: it supplies an enzymatic ingredient that remains inactive in low-moisture products and converts part of the sugar into fructooligosaccharides (FOS) — a recognised class of prebiotic fibre — once the food reaches the stomach. If replicated at scale and validated in humans, the idea could let manufacturers improve the post-consumption nutritional profile of legacy products such as chocolate, biscuits and confectionery without changing recipes or consumer experience.
Zya’s first ingredient, Convero, is an inulosucrase enzyme produced by precision fermentation and supplied as a dry powder. The company says the enzyme converts around 30% of sucrose in a finished product into FOS during digestion. That conversion occurs because the enzyme cleaves sucrose and links the fructose unit onto other sucrose molecules to build short-chain prebiotic fibres.
The technology is currently best suited to low-moisture applications — chocolate, cereal bars, biscuits and similar products — because exposure to water during processing or storage can activate the enzyme prematurely. Thermal processing can also inactivate enzymes, so Zya is working with manufacturers to identify processing steps that preserve Convero’s activity or ways to protect it through production.
Zya has demonstrated functionality in in-vitro gut models and preliminary pig studies, completed an independent toxicology programme including a 28-day rat feeding study and genotoxicity assessments (published in Toxicology Reports), and run feasibility projects with multinational food manufacturers. The company says it has more than 100 companies in its commercial pipeline and has scaled production to about 10 times its pilot runs at a European food-grade facility. Zya expects to complete a self-affirmed GRAS determination in the US by the end of 2026, followed by a formal GRAS submission to the FDA, and will use the new funding to progress further animal and human studies.
The round was led by Astanor, which also participated in Zya’s 2022 seed financing, with follow-on support from Ahren Innovation Capital, Red Bull Ventures, Zubi Capital, Phase Change and Meach Cove Capital. According to Zya, the funds will be deployed toward clinical validation, regulatory filings and commercial partnerships aimed at integrating Convero into existing manufacturer supply chains and finished products, ahead of planned US product launches in 2027.
In the announcement, Joshua Sauer, CEO at Zya, said:
We don’t just reduce sugar—we transform it into something beneficial.
In the announcement, Joshua Sauer, CEO at Zya, said:
I think the key thing for our investors was just the uniqueness of what we’re doing.
If you're researching potential backers in this space:
Zya was founded in 2018 by Oxford biochemists Joshua Sauer (CEO) and Niels Leckie (CSO). The founders frame Convero as an ingredient for the mass market rather than a niche functional add-on.
In the announcement, Joshua Sauer, CEO at Zya, said:
Convero is aimed at the mass market, not a niche functional-ingredient trend and takes a sugar surplus into the fiber Americans are short of.
Sauer has been candid about the technical hurdles ahead: demonstrating the conversion in humans, ensuring the enzyme survives or is shielded from industrial processing, and building a clear regulatory and labelling story that manufacturers can use without misleading consumers. On processing challenges, he said the team is exploring practical ways to preserve activity through existing production lines.
In the announcement, Joshua Sauer, CEO at Zya, said:
There are ways of us getting round certain processing steps that that may inactivate the enzyme.
Zya is one of several companies pursuing post-consumption strategies to reduce the metabolic impact of sugar. ZBiotics makes a genetically engineered probiotic that produces an enzyme in the gut; BioLumen develops microscopic sponges that physically trap sugars in the stomach; and researchers at the Wyss Institute have worked with Kraft Heinz on enzyme delivery systems designed to protect enzymes through the stomach and release them later. Zya’s route — supplying an extracted enzyme for manufacturers rather than a live microbe or a consumer-facing product — positions it as an industrial ingredient supplier to large food companies rather than a direct-to-consumer brand.
Regulatory and labelling questions remain central. Because Convero acts after ingestion, declared sugar on-pack would not change even if a portion of that sugar is converted to fibre post-consumption. Zya has suggested on-pack wording that explains post-consumption conversion and expects Convero to be declared on ingredient lists, likely as an inulosucrase enzyme with explanatory text.
This funding round reflects continued appetite among foodtech investors for ingredient-level innovations that let manufacturers improve nutritional profiles without sacrificing core product qualities. For UK and European foodtech ecosystems, Zya’s progress will be one to watch: success requires not only scientific validation and manufacturing scale but also workable regulatory and commercial pathways that large international brands can adopt.
| Investors | Investment Focus | Startup Investments | Round Size | Connect |
|---|---|---|---|---|
![]() Astanor Ventures( ) Astanor Capital focuses on transforming the agrifood system through innovation a... London | ||||
![]() Ahren Innovation Capital( ) Ahren is a venture capital firm specialising in deep technology and deep science... London | ||||
| All investors | All investor sectors | All funded startups | All funding rounds |
Click here for a full list of 7,589+ startup investors in the UK